AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 07-22 09:30:00 美东时间
0.249
-0.001
-0.40%
華盛通- 最 高0.2553
- 今 開0.25
- 成交量 62.08万股
- 最 低 0.2376
- 昨 收 0.25
- 總市值 690.33万
- 52周最高 3.0769
- 市盈率 靜 --
- 換手率 2.24%
- 52周最低 0.21
- 委 比 0.00%
- 總股本 2772.42万
- 歷史最高 20.3297
- 量 比 1.13
- 振 幅 7.08%
- 歷史最低 0.21
- 每 手 1
- 風險率 1.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Stockholders Approve Key Equity Proposals
AIM ImmunoTech ( ($AIM) ) just unveiled an update. On July 15, 2026, AIM Immuno...
07-17 17:18
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech Inc. announced the release of its latest CEO Corner segment, featuring CEO Thomas Equels discussing progress in pancreatic cancer treatment. Key points include successful patient enrollment and dosing in the DURIPANC Phase 2 study, encouraging interim results, favorable safety findings, Phase 3 planning, collaboration with AstraZeneca and Erasmus Medical Center, IP expansion, and Ampligen's potential in immunologically "cold" tumor...
07-07 13:03
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech Inc. announced the completion of enrollment in its Phase 2 DURIPANC trial combining Ampligen® with Imfinzi® for metastatic pancreatic cancer. The trial's primary endpoint, Clinical Benefit Rate, is expected to be analyzed by December 2026, with top-line results anticipated in Q1 2027. Secondary endpoints include overall survival, progression-free survival, and immune profiling. The company aims to use biomarker data to design a Pha...
06-18 13:01
AIM ImmunoTech Regains NYSE American Listing Compliance
The latest announcement is out from AIM ImmunoTech ( ($AIM) ). On June 12, 2026...
06-15 20:36
AIM ImmunoTech announces $2.65M financing priced at-market
AIM ImmunoTech (AIM) on Tuesday said it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gros...
06-09 21:54
AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 Shares
This prospectus relates to the offering and resale by the Selling Stockholders listed herein of up to an aggregate of 31,287,933 shares of our common stock, par value $0.001 per share (the "Common Stock"),
06-09 04:09
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
AIM ImmunoTech posts updated Ebola-focused investor presentation on website
AIM ImmunoTech posts updated Ebola-focused investor presentation on website AIM ImmunoTech published an Ebola-focused corporate presentation on Ampligen’s antiviral research, immune-modulating mechanism, preparedness positioning, and IV or intranasal human safety studies. The materials highlight pre
06-04 20:59
3 Penny Stocks Drawing Market Attention, 6/2/26
Hitek Global ($HKIT), Sphere 3D ($ANY), and AIM ImmunoTech ($AIM) are the three...
06-03 01:36
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
